Anti-tnf-α therapy may not improve arterial stiffness in patients with as: A 24-week follow-up

Rheumatology

Volumn 51, Issue 5, 2012, Pages 910-914

  Capkin, Erhan ^a   Karkucak, Murat ^a   Kiris, Abdulkadir ^a   Durmus, Ismet ^a   Karaman, Kayhan ^a   Karaca, Adem ^a   Tosun, Mehmet ^a   Ayar, Ahmet ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Ankylosing spondylitis; Anti TNF ; Arterial stiffness; Cardiovascular burden; Pulse wave velocity

Indexed keywords

ADALIMUMAB; ETANERCEPT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB;

ADULT; ANKYLOSING SPONDYLITIS; ARTERIAL STIFFNESS; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DISEASE DURATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PULSE WAVE; SYSTOLIC BLOOD PRESSURE;

ADULT; ANTI-INFLAMMATORY AGENTS; ARTERIES; BLOOD FLOW VELOCITY; BLOOD PRESSURE; FEMALE; HUMANS; MALE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR STIFFNESS;

EID: 84860241992     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker434     Document Type: Article

References (36)

1. Arnett FC. Ankylosing Spondylitis. In: Koopman WJ, ed. Arthritis and Allied Condition. Philadelphia: Lippincott Williams and Wilkins, 2001:1317.
2. Mathieu S, Joly H, Baron G et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology 2008;47: 1203-7.
3. Lautermann D, Braun J. Ankylosing spondylitis-cardiac manifestations. Clin Exp Rheumatol 2002;20:11-5.
4. Lehtinen K. Mortality and causes of death in 3 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993;52:174-6.
5. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine 2009; 88:358-65.
6. Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006;5:331-7.
7. Sari I, Okan T, Akar S et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 2006; 45:283-6.
8. van Eijk IC, Peters MJL, Serne EH et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor a blockade. Ann Rheum Dis 2009;68:362-6.
9. Moyssakis I, Gialafos E, Vassiliou VA et al. Myocardial performance and aortic elasticity are impaired in patients with ankylosing spondylitis. Scand J Rheumatol 2009;38: 216-21.
10. Capkin E, Kiris A, Karkucak M et al. Investigation of effects of different treatment modalities on structural and functional vessel wall properties in patients with ankylosing spondylitis. Joint Bone Spine 2011;78:378-82.
11. Wang X, Keith JC, Struthers AD et al. Assessment of arterial stiffness, a translational medicine biomarker system for evaluation of vascular risk. Cardiovasc Ther 2008;26: 214-23.
12. Caliskan M, Erdogan D, Gullu H et al. Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. Atherosclerosis 2008; 196:306-12.
13. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor a antibody. Arthritis Rheum 2004;51:447-50.
14. Hurlimann D, Forster A, Noll G et al. Anti-tumor necrosis factor-a treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106: 2184-7.
15. Gratacos J, Collado A, Filella X et al. Serum cytokines in ankylosing spondylitis: a close correlation between serum IL-and disease activity and severity. Br J Rheumatol 1994;33:927-31.
16. Yeboah J, Crouse JR, Hsu FC et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2007;115:2390-7.
17. Agewall S. Is impaired flow-mediated dilatation of the brachial artery a cardiovascular risk factor? Curr Vasc Pharmacol 2003;1:107-9.
18. Braun J, Sieper J. Treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009;27:146-7.
19. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
20. Braun J, Pham T, Sieper J et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
21. Wilkinson IB, Fuchs SA, Jansen IM et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 1998;16:2079-84.
22. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318-27.
23. Heeneman S, Daemen MJ. Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol 2007;19:358-62.
24. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862-73.
25. Laurent S, Cockcroft J, Van Bortel L et al. European Network for non-invasive investigation of large arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-2605.
26. Gedikli O, Kiris A, Ozturk S et al. Effects of prehypertension on arterial stiffness and wave reflections. Clin Exp Hypertens 2010;32:84-9.
27. Braun J, Baraliakos X, Listing J et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51.
28. Pieringer H, Stuby U, Pohanka E et al. Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with infliximab. Clin Rheumatol 2010; 29:723-7.
29. Angel K, Provan Sa, Hammer Hb et al. Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies. Fundam Clin Pharmacol 2011;25:511-7.
30. Syngle A, Vohra K, Sharma A et al. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade. Clin Rheumatol 2010;29:763-70.
31. Mäki-Petäjä KM, Hall FC, Booth AD et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006;114:1185-92.
32. Wong M, Oakley SP, Young L et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2009;68:1277-84.
33. Tikiz H, Arslan O, Pirildar T et al. The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis. Anadolu Kardiyol Derg 2010;10:98-103.
34. Galarraga B, Khan F, Kumar P et al. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. Rheumatology 2009;48:1418-23.
35. Van Doornum S, McColl G, Wicks IP. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology 2005;44: 1428-32.
36. Mathieu S, Dubost JJ, Tournadre A et al. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine 2010;77:50-2.